What is the primary advantage of using gadoxetate disodium in liver MRI?

What is the primary advantage of using gadoxetate disodium in liver MRI?

• A. Eliminates the need for gadolinium-based contrast.
• B. Reduces overall scan time by shortening sequences.
• C. Provides hepatobiliary phase enhancement to better characterize liver lesions and detect small lesions.
• D. Improves arterial enhancement alone without biliary information.

Answer: (C)

The main idea is that gadoxetate disodium provides a hepatobiliary phase, which makes liver parenchyma stand out on MRI and helps reveal and characterize lesions more clearly. This agent is taken up by functioning hepatocytes and excreted into bile, so after a short delay (around 20 minutes) the liver lights up on T1-weighted images while many lesions that lack normal hepatocytes or biliary excretion appear relatively dark. That differential enhancement improves detection of small lesions and helps distinguish lesion types, because benign lesions that have functioning hepatocytes (like focal nodular hyperplasia) become bright, whereas malignant lesions that don’t take up the agent often stay hypoenhanced. It also provides biliary information in addition to vascular information, which strengthens lesion characterization. Since it is still a gadolinium-based agent, it does not eliminate gadolinium use, and it doesn’t inherently shorten the scan time by itself, though it consolidates hepatobiliary assessment into the protocol.

The main idea is that gadoxetate disodium provides a hepatobiliary phase, which makes liver parenchyma stand out on MRI and helps reveal and characterize lesions more clearly. This agent is taken up by functioning hepatocytes and excreted into bile, so after a short delay (around 20 minutes) the liver lights up on T1-weighted images while many lesions that lack normal hepatocytes or biliary excretion appear relatively dark. That differential enhancement improves detection of small lesions and helps distinguish lesion types, because benign lesions that have functioning hepatocytes (like focal nodular hyperplasia) become bright, whereas malignant lesions that don’t take up the agent often stay hypoenhanced. It also provides biliary information in addition to vascular information, which strengthens lesion characterization. Since it is still a gadolinium-based agent, it does not eliminate gadolinium use, and it doesn’t inherently shorten the scan time by itself, though it consolidates hepatobiliary assessment into the protocol.